The Chemours Company

NYSE:CC Stock Report

Market Cap: US$2.3b

Chemours Management

Management criteria checks 2/4

Chemours' CEO is Denise M. Dignam, appointed in Feb 2024, has a tenure of 1.58 years. total yearly compensation is $5.89M, comprised of 15.4% salary and 84.6% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $3.00M. The average tenure of the management team and the board of directors is 2.2 years and 1.5 years respectively.

Key information

Denise M. Dignam

Chief executive officer

US$5.9m

Total compensation

CEO salary percentage15.36%
CEO tenure1.6yrs
CEO ownership0.1%
Management average tenure2.2yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

Chemours: Refrigerants Make This Company A Buy Before Q2 2025 Report

Aug 05

Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Chemours (NYSE:CC) Has No Shortage Of Debt

Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt

We Like The Quality Of Chemours' (NYSE:CC) Earnings

May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

What Is The Chemours Company's (NYSE:CC) Share Price Doing?

Mar 19
What Is The Chemours Company's (NYSE:CC) Share Price Doing?

It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

Mar 04
It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt

Jan 24
Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt

Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?

Jan 08
Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?

Not Many Are Piling Into The Chemours Company (NYSE:CC) Just Yet

Dec 05
Not Many Are Piling Into The Chemours Company (NYSE:CC) Just Yet

Chemours: Hasn't Been A Great Year, But The Long-Term Prospects Look Bright

Nov 21

Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye

Nov 12
Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye

Is It Too Late To Consider Buying The Chemours Company (NYSE:CC)?

Sep 25
Is It Too Late To Consider Buying The Chemours Company (NYSE:CC)?
User avatar

Shane Hostetter's CFO Role And TT Transformation Plan Promise Operational Excellence And Growth Surge

Operational efficiency improvements signaled by new CFO leadership and achievement in cost savings point towards better net margins and operating income.

Chemours: We're Back Down To Trough And A 'BUY'

Sep 01

Chemours: Upside After Irregularities, Good 2024-2026E

Jun 11

The Chemours Company's (NYSE:CC) Low P/S No Reason For Excitement

May 30
The Chemours Company's (NYSE:CC) Low P/S No Reason For Excitement

Drama At The Chemours Company Opens The Door For Upside

Mar 29

CEO Compensation Analysis

How has Denise M. Dignam's remuneration changed compared to Chemours's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$412m

Mar 31 2025n/an/a

US$28m

Dec 31 2024US$6mUS$904k

US$86m

Sep 30 2024n/an/a

US$68m

Jun 30 2024n/an/a

US$106m

Mar 31 2024n/an/a

-US$329m

Dec 31 2023US$2mUS$532k

-US$238m

Sep 30 2023n/an/a

-US$317m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

US$489m

Dec 31 2022US$2mUS$463k

US$578m

Compensation vs Market: Denise M.'s total compensation ($USD5.89M) is about average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Denise M.'s compensation has increased whilst the company is unprofitable.


CEO

Denise M. Dignam (59 yo)

1.6yrs
Tenure
US$5,887,980
Compensation

Ms. Denise M. Dignam serves as Independent Director at Kulicke and Soffa Industries, Inc. from August 22, 2023. She serves as Chief Executive Officer amd Director at The Chemours Company since March 25, 20...


Leadership Team

NamePositionTenureCompensationOwnership
Denise M. Dignam
President1.6yrsUS$5.89m0.13%
$ 3.0m
Shane Hostetter
Senior VP & CFO1.2yrsUS$1.35m0.0080%
$ 187.5k
Kristine Wellman
Senior VP2.9yrsUS$1.82m0.035%
$ 827.8k
Gerardo Calderon
President of Advanced Performance Materials2.4yrsUS$1.37m0.023%
$ 531.7k
Joseph Martinko
President of Thermal & Specialized Solutions2.2yrsUS$1.43m0.021%
$ 484.6k
David Will
Controller & Chief Accounting Officer1.1yrsno data0.0039%
$ 90.7k
Brandon Ontjes
Vice President of Investor Relations2.3yrsno datano data
Matthew Conti
Chief Human Resources Officerless than a yearno datano data
Aditya Beri
Interim President of Titanium Technologies & Chemical Solutions Business2.5yrsno datano data
Amber Wellman
Chief Sustainability Officer2.4yrsno datano data
Damian Gumpel
President of Titanium Technologiesless than a yearno data0.014%
$ 332.4k
2.2yrs
Average Tenure
50yo
Average Age

Experienced Management: CC's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Denise M. Dignam
President1.5yrsUS$5.89m0.13%
$ 3.0m
Mary Cranston
Independent Chair10.2yrsUS$282.50k0.0019%
$ 44.3k
Livingston Satterthwaite
Director1.3yrsUS$212.50k0%
$ 0
Alister Cowan
Lead Independent Director1.8yrsUS$265.00k0.0068%
$ 159.6k
Sean Keohane
Independent Director7.3yrsUS$282.50k0.0039%
$ 91.7k
George Brokaw
Directorless than a yearno data0.0094%
$ 220.8k
Joseph Kava
Directorless than a yearno datano data
Leslie Turner
Directorless than a yearno datano data
Courtney Mather
Directorless than a yearno data0.0094%
$ 220.8k
Erin Kane
Independent Director6.3yrsUS$282.50k0%
$ 0
Pamela Fletcher
Independent Director1.5yrsUS$304.99k0%
$ 0
1.5yrs
Average Tenure
58yo
Average Age

Experienced Board: CC's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/28 18:20
End of Day Share Price 2025/09/26 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

The Chemours Company is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAlembic Global Advisors
David ColemanArgus Research Company
Michael LeitheadBarclays